Due to a lack of data on clinical outcomes, the interim evaluation was unable to investigate whether Pilot participation affected clinical outcomes (e.g., diabetes, hypertension)
R.NettisE.PioggiaG.et al (2024)
5 and 6, samples in SDS solubilizer (0.0625 M TrisHCl (pH 6.8), 10% glycerol, 0.01% bromophenol blue, 2% (wt/vol) SDS, +/- 2% 2-mercaptoethanol) were heated at 95 C for 5 min, electrophoresed through 8% or 10% (wt/vol) polyacrylamide-SDS gels, transferred to nitrocellulose membranes (Bio-Rad, USA), and incubated with SARS-CoV-2 (2019-nCoV) S antibody rabbit PAb antigen affinity purified, mouse monoclonal anti-SARS-S2 conjugated to HRP, goat anti-human IgG-HRP, ACE2 recombinant rabbit monoclonal antibody, or purified LgBiT-substrate cocktail
Conversely, if a patient presents with pernicious anemia or severe neurological signssuch as intense tingling in the hands, memory loss, or muscle weaknessthe dosage remains the same (usually 1,000 mcg), but the frequency increases significantly
Of being dead within a year